Clinical trial · Interventional
Flubendazole Added to Standard Concurrent Chemoradiotherapy With Temozolomide in Patients With High-Grade Glioma
A Phase II Study of Adding Flubendazole to Standard Concurrent Chemoradiotherapy With Temozolomide in Patients With High-Grade Glioma
NCT07847476CI-TRIAL-00126685not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260930-000001
Summary
Brief summary (as posted)
This study To evalute the efficacy and safety of adding flubendazole to standard concurrent chemoradiotherapy with temozolomide in patients with high grade glioma and also to evaluate DFS,OS for those patients in clinical oncology department , Assiut university Hospital .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Flubendazole | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Flu
- description
- Flubendazole 100 mg twice daily for 3 day in the week for 6 weeks
- interventionNames
- Drug: Flubendazole
- type
- NO_INTERVENTION
- label
- Pt will receive concurrent chemo radiotherapy with TMZ with placebo
- description
- Pt will receive CCRth with TMZ with placebo
Primary outcomes (3)
- measure
- Incidence of treatment-related adverse events
- timeFrame
- From baseline until 30 days after completion of concurrent chemoradiotherapy
- description
- Treatment-related adverse events will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The number and severity of treatment-related adverse events occurring during concurrent chemoradiotherapy will be recorded
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * \- Age ≥18 years. * Male or female * Histologically confirmed high grade glioma (WHO grade 3(III) and grade 4 IV) after surgery. * ECOG PS 0-2 * Fit patient for concurrent chemoradiotherapy. Exclusion Criteria: * Age ≥80 years. * presence of another active malignancy . * known hypersensitivity to flubendazole. * pregnant or breastfeeding women. * inability to comply with study requirements.
References
Publications (0)
Data not yet available
No reference posted for this study.